IA
FBRX icon

Insight Advisors’s Forte Biosciences FBRX Stock Holding History

Insight Advisors’s Portfolio FBRX Stock Details FBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-766
Closed -$582K – 318
2021
Q2 		$582K Buy
766
+5
+0.7% +$4.51K 0.18% 148
2021
Q1 		$689K Buy
+761
New +$623K 0.22% 122

Other funds holding FBRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
OQS
Occudo Quantitative Strategies Fort Lauderdale, Florida $1.84B AUM 22.15% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
PPA
Parametric Portfolio Associates Seattle, Washington $190B AUM 18.52% 1-Year Est. Return

Insight Advisors's FBRX Position: Q3 2021 in Review

Insight Advisors sold out of Forte Biosciences (FBRX) in Q3 2021, closing a stake of 766 shares — an estimated $582K sold.

Insight Advisors first reported a position in FBRX in Q1 2021 and held it in 2 quarters. The position peaked at $689K in Q1 2021. 57 funds tracked by Wall St. Rank hold FBRX as of Q3 2021.

  • Insight Advisors reported no remaining Forte Biosciences position as of Q3 2021 after selling out during the quarter.
  • Insight Advisors sold 766 Forte Biosciences shares in Q3 2021, an estimated $582K.
  • Insight Advisors first reported a position in Forte Biosciences in Q1 2021 and held it in 2 quarters.
  • Insight Advisors's Forte Biosciences position peaked at $689K in Q1 2021.
  • 57 funds tracked by Wall St. Rank held Forte Biosciences as of Q3 2021.

Based on Insight Advisors's 13F filing for Q3 2021, filed 12 Nov 2021.